Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C

Hepatology

Volumn 48, Issue 5, 2008, Pages 1412-1419

  Morishima, Chihiro ^a   Morgan, Timothy R ^b,l   Everhart, James E ^c   Wright, Elizabeth C ^d   Apodaca, Minjun C ^a   Gretch, David R ^a   Shiffman, Mitchell I ^e   Everson, Gregory T ^f   Lindsay, Karen L ^g   Lee, William M ^h   Lok, Anna S F ⁱ   Dienstag, Jules L ^j   Ghany, Marc G ^d   Curto, Teresa M ^k  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k NEW ENGLAND RESEARCH INSTITUTES   (United States)

^l VA LONG BEACH HEALTHCARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ARTICLE; ASSAY; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; DRUG RESPONSE; DRUG WITHDRAWAL; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; RNA ANALYSIS; TRANSCRIPTION MEDIATED AMPLIFICATION ASSAY; TREATMENT DURATION; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; GENE AMPLIFICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; TRANSCRIPTION, GENETIC; VIRAL LOAD;

EID: 56149095245     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22487     Document Type: Article

References (19)

1. NIH Consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
2. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.
3. Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. HEPATOLOGY 1998;28:1121-1127.
4. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999;30:783-787.
5. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. HEPATOLOGY 2002;35:688-693.
6. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
7. Ross RS, Viazov SO, Hoffmann S, Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal 2001;15: 308-313.
8. Gorrin G, Friesenhahn M, Lin P, Sanders M, Pollner R, Eguchi B, et al. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. J Clin Microbiol 2003;41:310-317.
9. Hendricks DA, Friesenhahn M, Tanimoto L, Goergen B, Dodge D, Comanor L. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003;41: 651-656.
10. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. HEPATOLOGY 2006;44:360-367.
11. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. HEPATOLOGY 2000;32:818-823.
12. Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol 2001;39:2850-2855.
13. Comanor L, Anderson F, Ghany M, Perrillo R, Heathcote EJ, Sherlock C, et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001;96:2968-2972.
14. Gerotto M, Pero FD, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006;44:83-87.
15. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: Pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004;25:472-492.
16. Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol 2004;42:421-425.
17. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023.
18. Kadam JS, Gonzalez SA, Ahmed F, Menezes A, Jacobson IM. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin. Dig Dis Sci 2007;52:2525-2530.
19. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. HEPATOLOGY 2005;41:106-114.